Two Sigma Securities’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.59M | Buy |
5,761
+4,626
| +408% | +$3.15M | 0.31% | 55 |
|
|
2026
Q1 | $877K | Buy |
+1,135
| New | +$869K | 0.1% | 252 |
|
|
2025
Q4 | – | Sell |
-445
| Closed | -$250K | – | 1923 |
|
|
2025
Q3 | $250K | Sell |
445
-1,523
| -77% | -$861K | 0.04% | 679 |
|
|
2025
Q2 | $1.03M | Buy |
1,968
+1,024
| +108% | +$572K | 0.13% | 198 |
|
|
2025
Q1 | $599K | Sell |
944
-550
| -37% | -$378K | 0.09% | 289 |
|
|
2024
Q4 | $1.06M | Sell |
1,494
-206
| -12% | -$173K | 0.14% | 139 |
|
|
2024
Q3 | $1.79M | Buy |
+1,700
| New | +$1.89M | 0.03% | 593 |
|
|
2024
Q1 | – | Sell |
-7,967
| Closed | -$7.58M | – | 3531 |
|
|
2023
Q4 | $7M | Buy |
7,967
+7,681
| +2,686% | +$6.33M | 0.07% | 283 |
|
|
2023
Q3 | $235K | Sell |
286
-4,287
| -94% | -$3.37M | ﹤0.01% | 2161 |
|
|
2023
Q2 | $3.29M | Sell |
4,573
-1,490
| -25% | -$1.15M | 0.05% | 416 |
|
|
2023
Q1 | $4.98M | Buy |
+6,063
| New | +$4.57M | 0.1% | 238 |
|
|
2022
Q4 | – | Sell |
-1,171
| Closed | -$864K | – | 3146 |
|
|
2022
Q3 | $807K | Sell |
1,171
-99
| -8% | -$62.3K | 0.02% | 770 |
|
|
2022
Q2 | $751K | Sell |
1,270
-4,375
| -78% | -$2.84M | 0.03% | 676 |
|
|
2022
Q1 | $3.94M | Buy |
5,645
+3,034
| +116% | +$1.92M | 0.14% | 175 |
|
|
2021
Q4 | $1.65M | Buy |
2,611
+1,850
| +243% | +$1.14M | 0.07% | 151 |
|
|
2021
Q3 | $461K | Sell |
761
-493
| -39% | -$306K | 0.01% | 798 |
|
|
2021
Q2 | $700K | Buy |
1,254
+161
| +15% | +$81.6K | 0.02% | 514 |
|
|
2021
Q1 | $517K | Sell |
1,093
-441
| -29% | -$215K | 0.03% | 278 |
|
|
2020
Q4 | $741K | Buy |
1,534
+866
| +130% | +$467K | 0.02% | 501 |
|
|
2020
Q3 | $374K | Sell |
668
-6
| -0.9% | -$3.64K | 0.01% | 748 |
|
|
2020
Q2 | $420K | Buy |
+674
| New | +$383K | 0.01% | 709 |
|
|
2020
Q1 | – | Sell |
-1,032
| Closed | -$426K | – | 2123 |
|
|
2019
Q4 | $387K | Sell |
1,032
-3,629
| -78% | -$1.22M | ﹤0.01% | 1620 |
|
|
2019
Q3 | $1.29M | Buy |
4,661
+3,680
| +375% | +$1.09M | 0.01% | 767 |
|
|
2019
Q2 | $307K | Buy |
+981
| New | +$327K | ﹤0.01% | 1440 |
|
|
2019
Q1 | – | Sell |
-2,397
| Closed | -$987K | – | 2332 |
|
|
2018
Q4 | $895K | Sell |
2,397
-3,209
| -57% | -$1.17M | 0.01% | 689 |
|
|
2018
Q3 | $2.27M | Sell |
5,606
-680
| -11% | -$259K | 0.01% | 651 |
|
|
2018
Q2 | $2.17M | Buy |
6,286
+3,209
| +104% | +$1M | 0.01% | 883 |
|
|
2018
Q1 | $1.06M | Buy |
3,077
+2,172
| +240% | +$755K | 0.01% | 1226 |
|
|
2017
Q4 | $340K | Sell |
905
-134
| -13% | -$54.3K | 0.01% | 923 |
|
|
2017
Q3 | $465K | Buy |
1,039
+279
| +37% | +$133K | 0.04% | 275 |
|
|
2017
Q2 | $373K | Buy |
+760
| New | +$333K | 0.07% | 276 |
|
|
2016
Q4 | – | Sell |
-627
| Closed | -$252K | – | 900 |
|
|
2016
Q3 | $252K | Buy |
+627
| New | +$252K | 0.09% | 343 |
|
|
2016
Q1 | – | Sell |
-505
| Closed | -$274K | – | 373 |
|
|
2015
Q4 | $274K | Buy |
+505
| New | +$274K | 0.33% | 71 |
|
Other funds holding REGN
Two Sigma Securities's REGN Position: Q2 2026 in Review
Two Sigma Securities increased its Regeneron Pharmaceuticals (REGN) stake by 408% in Q2 2026, buying an estimated $3.15M and bringing the position to 5,761 shares worth $3.59M. The position accounts for 0.31% of the portfolio, ranked #55.
Two Sigma Securities first reported a position in REGN in Q4 2015 and has held it in 33 quarters since. The position peaked at $7M in Q4 2023. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Two Sigma Securities held 5,761 shares of Regeneron Pharmaceuticals worth $3.59M as of Q2 2026.
- Two Sigma Securities bought 4,626 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.15M.
- Regeneron Pharmaceuticals made up 0.31% of Two Sigma Securities's portfolio in Q2 2026, its #55 holding.
- Two Sigma Securities first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 33 quarters since.
- Two Sigma Securities's Regeneron Pharmaceuticals position peaked at $7M in Q4 2023.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.